Minalrestat
Modify Date: 2024-01-02 18:20:58
Minalrestat structure
|
Common Name | Minalrestat | ||
|---|---|---|---|---|
| CAS Number | 129688-50-2 | Molecular Weight | 449.20200 | |
| Density | 1.79g/cm3 | Boiling Point | 707.4ºC at 760mmHg | |
| Molecular Formula | C19H11BrF2N2O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 381.6ºC | |
Use of MinalrestatMinalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes[1]. |
| Name | 2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4,3'-pyrrolidine]-1,2',3,5'-tetrone |
|---|---|
| Synonym | More Synonyms |
| Description | Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Minalrestat (100 μM) 减少原代培养的大鼠系细胞内山梨糖醇含量，而不影响的细胞内葡萄糖含量[3]。 Minalrestat (100 μM, 48 h) 在原代培养的大鼠系膜细胞中引起 PKC-α 和 -β2 的积累[3]。 Western Blot Analysis[3] Cell Line: Primary cultured rat mesangial cells Concentration: 100 μM Incubation Time: 48 h Result: Increased accumulation of PKC-α and -β2. |
| In Vivo | Minalrestat (口服灌胃，10 mg/kg/天，持续 30 天) 可恢复糖尿病大鼠中降低的微血管反应性[1]。 Minalrestat (口服灌胃，10 mg/kg) 可恢复糖尿病大鼠毛细血管后微静脉中减少的白细胞粘附和迁移白细胞数量[2]。 Animal Model: Alloxan (40 mg/kg i.v.)-induced diabetic rats[1] Dosage: 10 mg/kg/day Administration: Oral gavage, for 30 days. Result: Restored the decreased microvascular reactivity. |
| References |
| Density | 1.79g/cm3 |
|---|---|
| Boiling Point | 707.4ºC at 760mmHg |
| Molecular Formula | C19H11BrF2N2O4 |
| Molecular Weight | 449.20200 |
| Flash Point | 381.6ºC |
| Exact Mass | 447.98700 |
| PSA | 83.55000 |
| LogP | 2.46090 |
| Vapour Pressure | 7.38E-20mmHg at 25°C |
| Index of Refraction | 1.689 |
| HS Code | 2933990090 |
|---|
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Minalrestat (USAN/INN) |
| Minalrestat |
| WAY-ARI-509 |
| Spiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone,2-((4-Bromo-2-fluorophenyl)methyl)-6-fluoro |
| Bffipt |